PDCD1 and type 1 diabetes mellitus: Interestingly, Teplizumab, which engages CD3 molecules on T cells, has been shown to increase the frequency of PD1+TIGIT+ T cells, and it was positively co-related with responders in the type 1 diabetes prevention trial (45).